IMRIS sells IMRISNV to Connecticut-based Yale-New Haven Hospital

World's First Installation of IMRISNV and IMRISneuro to be at New Smilow Cancer Hospital

IMRIS Inc. ("IMRIS" or the "Company") today announced the sale of IMRISNV to Connecticut-based Yale-New Haven Hospital (the "Hospital"), the primary teaching hospital for the Yale School of Medicine.

With installation later this year, Yale-New Haven Hospital will become the first hospital in the world with IMRISNV's unique capability of allowing both 3 Tesla MRI and bi-plane x-ray angiography in a single suite without the need to transport the patient between modalities. The IMRIS suite will be installed at the Hospital's new Smilow Cancer Hospital building and will include an interventional theater for neurovascular procedures, an MR diagnostic center and an operating room for neurosurgery. Earlier in the year, Yale-New Haven purchased an IMRISneuro system which will be part of the fully integrated suite.

The IMRIS suite features a bi-plane angiography system in the interventional theater and a wide bore 3T MRI scanner. The MRI can be deployed into any of the three rooms, permitting rapid and efficient transitions between MR imaging and surgery or intervention without transporting the patient between modalities. MR images can be taken before and during procedures to assess tissue condition, and can also be used in conjunction with fluoroscopic images during neurovascular procedures. On completion, new images can be taken to evaluate the surgery or intervention.

"Yale-New Haven Hospital has a strong reputation in the medical community and we are pleased that our systems have been selected for their new state of the art facility," said David Graves, President & CEO. "We continue to build our portfolio of leading edge, high value image guided solutions and offer products and room configurations that are tailored to meet each hospital's requirements. We are confident that the solution chosen by Yale-New Haven Hospital will provide tremendous value for their clinicians and patients across a number of applications."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Multiomic signatures identified for rapid detection and treatment of high-risk T-ALL